Search the Newsreel

Bioceres Crop Solutions (NASDAQ: BIOX) CEO logs 150,000-share equity gift

Bioceres Crop Solutions CEO Federico Trucco reported a bona fide gift transfer of 150,000 Ordinary Shares on May 20, 2026. These shares are held indirectly through Testamentario MQT Trust for the benefit of his child, with Trucco disclaiming beneficial ownership except for pecuniary interest. …

RioCan Real Estate Investment Trust Stock Climbs 0.73% as Retail Leasing Strength and Stable Rental Income Boost Investor Confidence

RioCan Real Estate Investment Trust 2026 Q2 - Results - Earnings Call Presentation (TSX:REI.UN:CA) 2026-08-06

BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside

BioCryst Pharmaceuticals, Inc.'s average 12-month price target has been lowered slightly from $21 to $20.82 by 11 analysts, with forecasts ranging from $12 to $32 per share. This new target suggests a potential upside of approximately 131% based on the Aug. 4 closing price. …

Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Dimensional Fund Advisors LP significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 119% in the first quarter, now holding 2.69 million shares valued at $25.6 million. This move is consistent with a generally positive outlook from analysts, who have assigned a "Moderate Buy" …

RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating

RBC Capital has adjusted its price target for BioCryst Pharmaceuticals (BCRX) to $13, down from $14, while maintaining an Outperform rating on the stock. This revision comes amidst recent company news, including the discontinuation of internal drug discovery programs and a positive earnings report …

BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength

BioCryst Pharmaceuticals (BCRX) reported a significant profit surge in Q2 2026, driven by strong ORLADEYO revenue and a European licensing deal, yet its stock remained largely unchanged. While ORLADEYO shows real patient uptake and the company has solid liquidity, concerns remain about its reliance …

BioCryst Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BCRX) 2026-08-06

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported strong Q2 results, with ORLADEYO revenue increasing 10% year-over-year and pediatric oral-pellet shipments commencing. The company maintained its 2026 ORLADEYO revenue outlook and reduced its non-GAAP operating cost guidance by ending internal drug discovery. BioCryst also completed enrollment for its …

Insiders In BioCardia Still Down 21% On US$1.08m Investment

Insiders at BioCardia, Inc. (NASDAQ:BCDA) are still down 21% on their US$1.08 million investment from the last year, despite a recent 23% stock gain. The largest purchase was by Independent Director Simon Stertzer for US$498k at US$1.25 per share, higher than the current US$0.95, …

Krebs Biochemicals & Industries reports standalone net loss of Rs 2.48 crore in the June 2026 quarter

Krebs Biochemicals narrows Q1FY26 net loss 53% on revenue surge

RioCan Real Estate Investment Trust (TSE:REI.UN) Stock Passes Above 200-Day Moving Average - Here's Why

Biocon shares rise 4% as Q1 net profit jumps 53%

Biocon Shares Surge Nearly 3% After Q1 Profit Jumps 350%

Krebs Biochemicals Q1 Results: Net loss narrows to ₹248 lakh as revenue rises

RioCan Real Estate Investment Trust (TSE:REI.UN) Price Target Raised to C$22.50

Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

RioCan (TSX:REI.UN) Stock Price Faces A Tougher FFO Debate After Guidance Lift

AudioCodes Posts Q2 2026 Growth, Boosts Voice AI and Announces Semi-Annual Dividend

AudioCodes (AUDC) reported modest top-line growth in Q2 2026, with revenue up 3.1% to $63 million, driven by its voice AI-driven cloud software and services model. The company's annual recurring revenue reached $84 million, a 20% increase year-on-year, and it announced a semi-annual dividend …

PRE-MARKET INDIAN STOCKS NEWS: Earnings including Aurobindo Pharma, Biocon and PB Fintech

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue reaching $218.3 million and ORLADEYO net revenue at $158.2 million, leading to an operating profit of $98.5 million. The company maintained its full-year ORLADEYO revenue guidance and increased total revenue guidance, while …

Iochpe-Maxion (MYPK3): Tendências mistas, resultados estáveis; revisão do 2T26

Iochpe-Maxion (MYPK3) registra lucro de R$ 86,9 mi no 2T26

Riocan Real Estate Investment Trust (RIOCF) (Q2 2026) Earnings Call Highlights: Record ...

This article first appeared on GuruFocus. Core FFO: $0.40 per unit in Q2 2026, up 5.3% year over year. Commercial Same-Property NOI Growth: Increased 4.3% year over year, contributing $0.02 per unit. Core FFO Payout Ratio: 73.8% on a trailing 12-month basis, down approximately …

BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Completed enrollment of the largest blinded hereditary angioedema (HAE) trial ever for Navenabar ahead of …

BioCardia to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 12 Conference Call

BioCardia, Inc. will host a conference call on August 12, 2026, at 4:30 PM EDT to discuss its second-quarter 2026 financial results and provide a corporate update. The call will include a presentation, a Q&A session, and will be accessible via registration, dial-in numbers, …

BioCardia Sets Live Webcast for Q2 Results on Aug. 12

BioCardia (NASDAQ:BCDA) will host a conference call on Wednesday, August 12, 2026, at 4:30 PM EDT to discuss its Q2 2026 financial results and provide a corporate update. Investors can register online for dial-in details or join by phone or live webcast, with replays …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results

Audiocodes (AUDC) investor files to sell 8,436 shares after RSU vesting

An Audiocodes (AUDC) investor has filed a Form 144 notice to sell 8,436 ordinary shares through Oppenheimer & Co Inc on August 5, 2026, with an indicated value of $84,697.44. These shares originated from the vesting of Restricted Stock Units (RSUs) on various dates …

Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook

BioCryst Pharmaceuticals reported Q2 2026 earnings that surpassed Wall Street expectations, with adjusted earnings of $0.30 per share against an estimated $0.16, and revenue of $218.3 million compared to a forecast of $185.69 million. The company raised its full-year 2026 revenue guidance to $690 …

Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M

Earnings Call Insights: BioCryst Pharmaceuticals (BCRX) Q2 2026 MANAGEMENT VIEW * "During the second quarter, we continued to execute effectively on the commercial and development fronts. We completed the integration of Astria Therapeutics and we further increased our cash generations through growing revenue and …

AudioCodes (AUDC) insider Niran Baruch plans sale of 5,625 vested shares

AudioCodes Ltd (AUDC) insider Niran Baruch has filed to sell 5,625 ordinary shares through Oppenheimer & Co. Inc. on or after August 5, 2026, with an estimated market value of $56,475.00. These shares stem from vested Restricted Stock Units (RSUs) from previous tranches in …

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M

BioCryst Pharmaceuticals, Inc. (BCRX) reported Q2 revenue of $218.2 million, significantly exceeding FactSet's estimate of $183.3 million. The company also updated its earnings guidance for the full year 2026 and announced increased Q2 earnings and revenue. Additionally, Wedbush adjusted BioCryst Pharmaceuticals' price target to …

AudioCodes (NASDAQ: AUDC) sets 2026 AGM with director and auditor votes

AudioCodes Ltd. (NASDAQ: AUDC) will hold its 2026 Annual General Meeting of Shareholders on September 9, 2026, in Or Yehuda, Israel. Key agenda items include the re-election of Class II directors Joseph Tenne and Shira Fayans Birenbaum for three-year terms and the ratification of …

BioCryst Starts Shipping ORLADEYO Oral Pellets to Pediatric Patients

BioCryst Pharmaceuticals reported strong Q2 2026 financial results, with total revenue up 34% year-over-year to $218.3 million and ORLADEYO revenue reaching $158.2 million. The company has begun shipping ORLADEYO oral pellets to pediatric HAE patients and raised its full-year total revenue guidance while lowering …